IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a Healthcare company (Biotechnology) with a market capitalization of $2.6B. The Maz Rating grades it against the other companies in its sector.
IDEAYA Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $27.40, IDEAYA Biosciences, Inc. trades at 72.1x sales and 2.6x book value. Over the last twelve months it generated about $37M of revenue and a net loss of $437M. It runs an operating margin of -1267.4% and a net margin of -1149.6%. It shows return on equity of -39.5%, return on invested capital of -41.3% and a free cash flow yield of -13.2%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 9.04. Over the past 52 weeks the share price ranged from $26.69 to $42.68, with a beta of -0.09.
IDEAYA Biosciences, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 24 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, IDEAYA Biosciences, Inc. (IDYA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 33.8% / 30% · Interest income / Revenue 116.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 24.7% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 116.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 24.7% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 116.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 1.21% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 63.8% / 33.33% · Receivables / Avg Assets (4Q) 0.60% / 33.33% · Interest income / Revenue 116.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 69.0% / 33.33% · (Cash+Recv) / Total Assets 69.0% / 33.33% · Interest income / Revenue 116.0% / 5% | Fail |
No. As of September 2026, IDEAYA Biosciences, Inc. (IDYA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. IDEAYA Biosciences, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 116.0% of each dividend: IDEAYA Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.